Overview

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

Status:
Completed
Trial end date:
2017-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
Phase:
Early Phase 1
Details
Lead Sponsor:
Carla Greembaum, MD
Carla Greenbaum, MD
Collaborator:
Janssen Research & Development, LLC
Treatments:
Antibodies, Monoclonal
Siltuximab